HBB抗体;HBB Antibody—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Mouse liver tissue, Human heart tissue and Human plasma solution lysates, Primary antibody: P13498(HBB Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13498(HBB Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Hemoglobin subunit beta (HBB) antibodies are essential tools in studying hemoglobin structure, function, and related disorders. HBB encodes the β-globin chain of hemoglobin, a tetrameric protein critical for oxygen transport in red blood cells. Mutations in HBB cause hemoglobinopathies like sickle cell disease (caused by the HBBV6E mutation) and β-thalassemia (due to reduced β-globin synthesis). Antibodies targeting HBB are widely used to detect, quantify, and analyze β-globin expression in research and diagnostics.

In research, HBB antibodies enable investigations into hemoglobin synthesis, erythroid differentiation, and disease mechanisms. They are employed in techniques such as Western blotting, ELISA, and immunohistochemistry to assess protein levels in cell/tissue samples. Clinically, these antibodies aid in diagnosing hemoglobin variants and monitoring disease progression. They also support newborn screening programs for early detection of hemoglobinopathies.

Recent therapeutic advances, including gene-editing therapies (e.g., CRISPR-Cas9) targeting HBB, have increased demand for specific antibodies to validate β-globin restoration in preclinical studies. Additionally, HBB antibodies contribute to quality control in blood transfusion products and research on hemoglobin’s role in conditions like malaria susceptibility. Their specificity and versatility make HBB antibodies indispensable in both basic science and translational medicine.